Both are much harder to manage if the team finds out on day four of stimulation
This test examines how your GLP1R rs6923761, GIPR rs1800437, and other peptide-pathway variants influence your individual response to therapy, helping your provider anticipate whether you will need aggressive protein planning or more moderate intervention
At minimum, request a fasting glucose test, A1C, complete lipid panel (total cholesterol, LDL, HDL, triglycerides), liver enzyme panel (ALT, AST), complete blood count, and a basic metabolic panel
Rybelsus and Trulicity are both FDA-approved GLP-1 receptor agonists that help regulate blood sugar levels in patients with type 2 diabetes, but they differ significantly in administration: Rybelsus is the first oral semaglutide (taken as a daily pill), while Trulicity (dulaglutide) requires a weekly injection